洛铂单药治疗非小细胞肺癌要点讲解.docVIP

洛铂单药治疗非小细胞肺癌 刘卓星1，程越，杨海劲，田丹，黄国庆 （河源市人民医院肿瘤中心 河源，517000） 【摘要】 目的 探讨洛铂单药方案对晚期非小细胞肺癌的临床疗效。方法 选择初治的IllB～IV期非小细胞肺癌（NSCLC），予以4周期含洛铂两药方案化疗后病情未进展的患者（完全缓解者剔除）58例分为对照组 (n=28)和观察组 (n=30)，对照组仅予最佳支持关怀治疗（BSC）；观察组予洛铂30mg/m2，第1天，静脉滴注，21天为1个周期同时给予最佳支持关怀治疗。治疗至病情进展。以中位无进展生存时间(PFS)、生活质量（QOL）和不良反应作为观察指标。观察组患者至少完成3个周期的维持治疗，最多5个周期，共完成131个周期。结果 观察组的PFS为6.2个月，较对照组的2.9个月长，差异显著(P0．05)。观察组QOL好转率为63.3%，高于对照组的42.9%差异显著(P0．05)。不良反应两组比较无统计学差异（P0．05)。结论 洛铂单药用于晚期NSCLC的维持治疗能够延长PFS，提高QOL，不良反应可以耐受。 【关键词】洛铂；非小细胞肺癌；维持治疗 A Study of Lobaplatin as a single agent in the maintenance treatment of non-small cell lung cancer 1通讯作者，广东省河源市人民医院肿瘤中心，河源 517000 E-mail:liuzhuoxing@ Liu zhuo-xing1, Cheng yue, Yang hai-jing, Tian dan, Huang guo-qing. Department of Oncology, Heyuan peoples hospital,Heyuan 517000 ,China [Abstract] [Objective] To study the efficiency and adverse effects of using lobaplatin to treat non-small cell lung cancer. ?[Methods] Choice of initial treatment of IllB ~ IV stage non small cell lung cancer (NSCLC) patients failed to progress, to 4 cycle containing platinum containing lobaplatin chemotherapy (complete remission after eliminating) 58 cases were divided into control group (n=28) and observation group (n=30), the control group only received best supportive care treatment; observation group was treated with lobaplatin 30mg/m2, first days, intravenous drip, 21 days are 1 period also received best supportive care treatment. Progress in the treatment to the disease. The median progression free survival time (PFS), quality of life (QOL) and adverse reaction as observed indexes. The observation group patients completed at least 3 cycles of maintenance therapy, 5 cycles at most, completed a total of 131 cycles. [Results] The observation group PFS was 6.2 months, compared with the control group, 2.9 month longer (P0.05). The observation group QOL improvement rate was 63.3%, 42.9% higher than that of the control group were significantly different (P0.05).Adverse reactions of the two groups h